Manufacturers report topline results from study 211 supporting 24 mg as appropriate starting dose for lenvatinib in patients with differentiated thyroid cancer

The post-marketing phase 2 trial found that an 18 mg starting dose did not meet the non-inferiority requirement in terms of objective response rate at week 24 in patients with RAI-refractory differentiated thyroid cancer compared to the currently licensed 24 mg dose


Biospace Inc.